These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1234 related items for PubMed ID: 29735299

  • 1. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, EURO-SKI investigators.
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [Abstract] [Full Text] [Related]

  • 2. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
    Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M.
    Lancet Haematol; 2017 Jul; 4(7):e310-e316. PubMed ID: 28566209
    [Abstract] [Full Text] [Related]

  • 3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chroniques.
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [Abstract] [Full Text] [Related]

  • 4. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [Abstract] [Full Text] [Related]

  • 5. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.
    J Clin Oncol; 2014 Feb 10; 32(5):424-30. PubMed ID: 24323036
    [Abstract] [Full Text] [Related]

  • 6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.
    Lancet Oncol; 2011 Sep 10; 12(9):841-51. PubMed ID: 21856226
    [Abstract] [Full Text] [Related]

  • 7. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT, Cortes JE, Kantarjian HM.
    Lancet Haematol; 2019 Aug 10; 6(8):e398-e408. PubMed ID: 31208943
    [Abstract] [Full Text] [Related]

  • 8. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S, Udre I, Rivkina A.
    Exp Oncol; 2017 Jul 10; 39(2):151-154. PubMed ID: 29483494
    [Abstract] [Full Text] [Related]

  • 9. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 10. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
    Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y, DADI Trial Group.
    Lancet Haematol; 2020 Mar 15; 7(3):e218-e225. PubMed ID: 31978329
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
    Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S, DADI Trial Group.
    Lancet Haematol; 2015 Dec 15; 2(12):e528-35. PubMed ID: 26686407
    [Abstract] [Full Text] [Related]

  • 13. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X, Qin Y, Huang X, Jiang Q.
    Oncologist; 2019 Nov 15; 24(11):e1141-e1147. PubMed ID: 31186377
    [Abstract] [Full Text] [Related]

  • 14. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX, France Intergroupe des Leucémies Myéloïdes Chroniques.
    Blood; 2017 Feb 16; 129(7):846-854. PubMed ID: 27932374
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.
    J Clin Oncol; 2017 Jan 20; 35(3):298-305. PubMed ID: 28095277
    [Abstract] [Full Text] [Related]

  • 16. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
    Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, Berk S, Erdogan Ozunal I, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Ozbek U, Aydin Y.
    Clin Lymphoma Myeloma Leuk; 2019 Jul 20; 19(7):e377-e384. PubMed ID: 31088736
    [Abstract] [Full Text] [Related]

  • 17. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.
    Cancer; 2017 Jul 01; 123(13):2482-2488. PubMed ID: 28241101
    [Abstract] [Full Text] [Related]

  • 18. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, Systchenko T, Maillard N, Desmier D, Machet A, Fleck E, Corby A, Motard C, Denis G, Herbelin A, Gombert JM, Roy L, Ragot S, Leleu X, Guilhot F, Chomel JC.
    Cancer; 2020 Aug 01; 126(15):3438-3447. PubMed ID: 32459375
    [Abstract] [Full Text] [Related]

  • 19. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S, Tremblay D, Mascarenhas J.
    Clin Lymphoma Myeloma Leuk; 2016 Sep 01; 16(9):488-494. PubMed ID: 27406834
    [Abstract] [Full Text] [Related]

  • 20. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M, Soverini S, De Benedittis C.
    Am Soc Clin Oncol Educ Book; 2014 Sep 01; ():167-75. PubMed ID: 24857074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.